Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 11/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 3/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5653771 | 0.92 | KDR (0.41) | FLT1KDRFGFR1PDE10APDGFRB | |
| SCHEMBL4791838 | 0.87 | KDR (0.44) | FLT1KDRFGFR1PDE10APDGFRB | |
| SCHEMBL5652542 | 0.85 | PDGFRB (0.47) | PDE10APDGFRB | |
| SCHEMBL4791470 | 0.82 | PDGFRB (0.45) | FLT1KDRFGFR1PDE10APDGFRB | |
| SCHEMBL4795126 | 0.81 | PDE10A (0.45) | FLT1KDRFGFR1PDE10AKDM1A | |
| SCHEMBL4977732 | 0.81 | IRAK4 (0.42) | PDE10APDGFRB | |
| SCHEMBL4975789 | 0.80 | FLT1 (0.44) | FLT1KDRFGFR1PDE10APDGFRB | |
| SCHEMBL5479282 | 0.80 | FLT1 (0.46) | FLT1KDRFGFR1PDE10APDGFRB | |
| SCHEMBL5653371 | 0.79 | PDE10A (0.47) | PDE10APDGFRBPDPK1 | |
| SCHEMBL4778162 | 0.78 | FLT1 (0.41) | FLT1KDRFGFR1PDE10APDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-15 | — | — | US | disclosed |
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-15 | — | — | US | disclosed |
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-15 | — | — | US | disclosed |
| WO-2007098214-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | PDE7A, PDE10A, PDE7B | FLT1 4513/4885KDR 4682/4885FGFR1 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.